EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia, and airway hyperresponsiveness in mice



Effect of an orally active Th1/Th2 balance modulator, M50367, on IgE production, eosinophilia, and airway hyperresponsiveness in mice



Journal of Immunology 162(12): 7470-7479



We have found a novel anti-allergic agent, M50367, which suppresses IgE biosynthesis and eosinophil accumulation in vivo. In this study, we evaluated the ability of M50367 to modulate Th1/Th2 balance in Th2-background BALB/c mice and to inhibit airway hyperresponsiveness in a murine model of atopic asthma. Oral M50367 at 3-30 mg/kg/day exhibited 51 to 73% reduction of IL-4/IL-5 production and 2- to 5-fold augmentation of IFN-gamma production by Ag-stimulated cultured splenocytes of the mice sensitized with DNP-Ascaris. These alterations in Th1/Th2 cytokine production were accompanied by 55-85% suppression of plasma IgE level. Oral M50367 at a dose of 10 mg/kg/day significantly inhibited Ig-independent peritoneal eosinophilia by 54%, which was induced by repeated i.p. injections of Ascaris suum extract. To develop airway hyperresponsiveness caused by allergic airway inflammation, BALB/c mice were sensitized with i.p. OVA injections, followed three times by OVA inhalation. Oral M50367 significantly inhibited the increase in airway reactivity to acetylcholine, together with the elevation of plasma IgE level and pulmonary eosinophilia, which were observed in vehicle-treated mice 1 day after the last inhalation. Moreover, M50367 treatment reduced IL-4 and IL-5 production and tended to enhance IFN-gamma production, not only by cultured splenocytes, but also in bronchoalveolar lavage fluid. These results suggest that M50367 has a modulating ability of Th1/Th2 balance to down-regulate Th2 response in the circulating system as well as at the sites of inflammation, and may be beneficial for the treatment of allergic disorders such as atopic asthma.

(PDF 0-2 workdays service: $29.90)

Accession: 017870672

Download citation: RISBibTeXText

PMID: 10358202



Related references

Effect of M50367, a novel antiallergic agent, on airway eosinophilia and hyperresponsiveness in ovalbumin-sensitized mice. Journal of Allergy & Clinical Immunology 101(1 PART 2): S62, 1998

An orally active Th1/Th2 balance modulator, M50367, suppresses Th2 differentiation of naive Th cell in vitro. Cellular Immunology 224(1): 29-37, July, 2003

Effect of anti-IL-5 monoclonal antibody on allergic bronchial eosinophilia and airway hyperresponsiveness in mice. Life Sciences. 53(15): 243-247, 1993

Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. American Journal of Respiratory and Critical Care Medicine 163(3 Pt 1): 721-730, 2001

Lack of airway hyperresponsiveness and airway eosinophilia in STAT6 deficient mice is overcome by IL-5. Journal of Allergy & Clinical Immunology 103(1 PART 2): S202, 1999

Eotaxin-1-deficient mice develop airway eosinophilia and airway hyperresponsiveness. International Archives of Allergy and Immunology 126(2): 119-125, 2001

The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. American Journal of Respiratory and Critical Care Medicine 160(4): 1283-1291, 1999

Kinetics of airway hyperresponsiveness and airway eosinophilia in BALB/c mice and their modulation by different dexamethasone treatment regimens. Pulmonary Pharmacology & Therapeutics 15(5): 467-475, 2002

Eotaxin-deficient mice develop airway eosinophilia and airway hyperresponsiveness following ovalbumin sensitization and challenge. Journal of Allergy & Clinical Immunology 105(1 part 2): S248, 2000

Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. Journal Of Allergy & Clinical Immunology. 102(1): 86-93, Y, 1998

Inhalation of inactivated‑Mycobacterium phlei prevents asthma‑mediated airway hyperresponsiveness and airway eosinophilia in mice by reducing IL‑5 and IL‑13 levels. Molecular Medicine Reports 14(6): 5343-5349, 2016

Effect of KW-4679, an orally active anti-allergic drug, on antigen-induced airway hyperresponsiveness in actively sensitized guinea pigs. Japanese Journal of Pharmacology 70(3): 277-280, 1996